| Original language | English (US) |
|---|---|
| Pages (from-to) | 1162-1164 |
| Number of pages | 3 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 129 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2012 |
| Externally published | Yes |
Bibliographical note
Funding Information:Supported by National Institutes of Health grants R01 HL61879, P01 HL70831, M01 RR03186, and 1UL1RR025011 from the Clinical and Translational Science Award (CTSA) program of the National Center for Research Resources (NCRR) .
Funding Information:
Disclosure of potential conflict of interest: R. F. Lemanske, Jr, is a speaker for Merck, AstraZeneca, Doembecher Children’s Hospital, Washington University, the Medicus Group, Park Nicolet Institute, the American College of Allergy, Asthma & Immunology, the Los Angeles Allergy Society, the Michigan Allergy/Asthma Society, the Medical College of Wisconsin, the Fund for Medical Research and Education (Detroit), Children’s Hospital of Minnesota, the Toronto Allergy Society, the American Academy of Allergy, Asthma & Immunology, Beaumont Hospital (Detroit), University of Illinois, the Canadian Society of Allergy and Clinical Immunology, New York Presbyterian, the Med Media Educational Group, Onpointe Medical Communications, the Medical University of South Carolina, Health Matters Communication, Bishop McCann, Donohue, Purohit, Miller, the Center for Health Care Education, University of California—San Francisco, the American Thoracic Society, the University of Iowa, Indiana University, the American Lung Association of the Upper Midwest, Vanderbilt University, Rochester Children’s Hospital, the Colorado Allergy Society, the Pennsylvania Allergy Society, Howard Pilgrim Health Care, and the California Allergy Society; has consultant arrangements with AstraZeneca, Map Pharmaceuticals, Gray Consulting, Smith Research, the Merck Childhood Asthma Network, Novartis, Quintiles/Innovex, RC Horowitz & Co, International Meetings and Science, Scienomics, Scientific Therapeutics, Cognidmed, SA Boney and Associates, GlaxoSmithKline, and Double Helix Development; is an author for Up-to-Date; is a textbook editor for Elsevier; and receives royalties from Elsevier. J. E. Gern is on the scientific advisory board for and has stock options with 3V Biosciences; has consultant arrangements with Centocor, Boehringer Ingelheim, GlaxoSmithKline, Biota, MedImmune, and Theraclone; and receives research support from AstraZeneca and GlaxoSmithKline . D. J. Jackson receives research support from Pharmaxis, the National Institutes of Health, and the American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline . The rest of the authors declare that they have no relevant conflicts of interest.